Financial report context:
purchases of short-term marketable securities , net of sales of short-term marketable securities during the quarter . additionally , we incurred $ 3.8 million related to cash expenditures for property and equipment primarily on computer software projects and manufacturing equipment related to our expansion in ireland . our financing activities during the year ended march 31 , 2009 provided cash of $ 46.2 million as compared to $ 2.1 million during the same period in the prior year . cash provided by financing activities for the year ended march 31 , 2009 was primarily comprised of $ 42.0 million in net proceeds related to our august 2008 public offering and $ 5.0 million attributable to the exercise of stock options and proceeds from our employee stock purchase plan . capital expenditures for fiscal 2010 are estimated to be $ 2.5 to $ 3.0 million , which relate primarily to our planned manufacturing capacity increases for impella in germany , our expansion in ireland , and software development projects . our liquidity is influenced by our ability to sell our products in a competitive industry and our customers 2019 ability to pay for our products . factors that may affect liquidity include our ability to penetrate the market for our products , maintain or reduce the length of the selling cycle , and collect cash from clients after our products are sold . exclusive of activities involving any future acquisitions of products or companies that complement or augment our existing line of products , we believe that current available funds and cash generated from operations will provide sufficient liquidity to meet operating requirements for the foreseeable future . we believe that our existing cash balances and cash flow from operations will be sufficient to meet our projected capital expenditures , working capital , and other cash requirements at least through the next 12 months . we continue to review our long-term cash needs on a regular basis . currently , we have no debt outstanding . contractual obligations and commercial commitments the following table summarizes our contractual obligations at march 31 , 2009 and the effects such obligations are expected to have on our liquidity and cash flows in future periods . payments due by fiscal year ( in $ 000 2019s ) contractual obligations total than 1 than 5 .

Financial table:
contractual obligations: operating lease commitments; payments due by fiscal year ( in $ 000 2019s ) total: $ 10690; payments due by fiscal year ( in $ 000 2019s ) less than 1 year: $ 2313; payments due by fiscal year ( in $ 000 2019s ) 1-3 years: $ 4267; payments due by fiscal year ( in $ 000 2019s ) 3-5 years: $ 2592; payments due by fiscal year ( in $ 000 2019s ) more than 5 years: $ 1518
contractual obligations: contractual obligations ( 1 ); payments due by fiscal year ( in $ 000 2019s ) total: 9457; payments due by fiscal year ( in $ 000 2019s ) less than 1 year: 4619; payments due by fiscal year ( in $ 000 2019s ) 1-3 years: 4838; payments due by fiscal year ( in $ 000 2019s ) 3-5 years: 2014; payments due by fiscal year ( in $ 000 2019s ) more than 5 years: 2014
contractual obligations: total obligations; payments due by fiscal year ( in $ 000 2019s ) total: $ 20147; payments due by fiscal year ( in $ 000 2019s ) less than 1 year: $ 6932; payments due by fiscal year ( in $ 000 2019s ) 1-3 years: $ 9105; payments due by fiscal year ( in $ 000 2019s ) 3-5 years: $ 2592; payments due by fiscal year ( in $ 000 2019s ) more than 5 years: $ 1518

Additional report context:
( 1 ) contractual obligations represent future cash commitments and expected liabilities under agreements with third parties for clinical trials . we have no long-term debt , capital leases or other material commitments for open purchase orders and clinical trial agreements at march 31 , 2009 other than those shown in the table above . in may 2005 , we acquired all the shares of outstanding capital stock of impella cardiosystems ag , a company headquartered in aachen , germany . the aggregate purchase price excluding contingent payments , was approximately $ 45.1 million , which consisted of $ 42.2 million of our common stock , $ 1.6 million of cash paid to certain former shareholders of impella and $ 1.3 million of transaction costs , consisting primarily of fees paid for financial advisory and legal services . at the time of the transaction , we agreed to make additional contingent payments to impella 2019s former shareholders based on additional milestone payments related to product sales and fda approvals in the amount of up to $ 16.8 million . in january 2007 upon the sale of 1000 impella units , we paid $ 5.6 million in the form of common stock . in june 2008 we received 510 ( k ) clearance of our impella 2.5 , and we paid $ 5.6 million in the form of common stock . in april 2009 , we received 501 ( k ) clearance of our impella 5.0 , triggering an obligation to make the final$ 5.6 million milestone payment . on may 15 , 2009 , we paid $ 1.75 million of this final milestone in cash and elected to pay the remaining amount through the issuance of approximately 664612 shares of our common stock . this contingent payment will result in an increase to the carrying value of goodwill . in june 2008 , we amended the lease for our facility in danvers , massachusetts . the amendment extended the lease from february 28 , 2010 to february 28 , 2016 . the lease continues to be accounted for as an operating lease . the amendment changed the rent payments under the lease from $ 64350 per month to the following schedule : 2022 the base rent for july 2008 through october 2008 was $ 0 per month ; 2022 the base rent for november 2008 through june 2010 is $ 40000 per month ; 2022 the base rent for july 2010 through february 2014 will be $ 64350 per month ; and 2022 the base rent for march 2014 through february 2016 will be $ 66000 per month. .

Question: what are the total contractual commitments , in millions?
Answer: 40294